文献速递临床试验与 GCP真实世界研究与卫生经济

结膜下曲安奈德注射与玻璃体内地塞米松植入剂治疗炎性黄斑水肿的随机对照试验方案

Comparison of two techniques used in routine care for the treatment of inflammatory macular oedema, subconjunctival triamcinolone injection and intravitreal dexamethasone implant: medical and economic importance of this randomized controlled trial.
PubMed 文献 · Trials · 2020-02-10

本随机对照试验计划纳入142例炎性黄斑水肿患者,比较结膜下曲安奈德注射与玻璃体内700μg地塞米松植入剂的有效性和安全性,随访6个月每月评估。若前者不劣于后者且不增加副作用,将具有重要公共卫生意义。

要点

  • 比较结膜下曲安奈德与玻璃体内地塞米松植入剂治疗炎性黄斑水肿。
  • 计划纳入142例患者,随机分组,随访6个月每月访视。
  • 评估视觉 acuity、眼压、激光闪辉和OCT等指标。

核心结论

  • 该试验旨在比较两种眼周与眼内皮质类固醇注射策略治疗炎性黄斑水肿的有效性和安全性。
  • 若结膜下曲安奈德注射(费用2.84欧元)不劣于地塞米松700μg植入剂(约960欧元)且不增加副作用,将对公共卫生产生实际影响。

研究设计与样本

  • 随机对照试验方案,计划纳入142例炎性黄斑水肿患者。
  • 患眼随机接受结膜下曲安奈德注射或玻璃体内700μg地塞米松植入剂治疗。
  • 随访6个月,每月访视,评估视力、裂隙灯、眼底镜、眼压、激光闪辉和谱域OCT。

临床怎么用

  • 该试验结果将为炎性黄斑水肿的皮质类固醇治疗策略选择提供有效性和安全性证据。
  • 若结膜下曲安奈德注射被证实不劣效,可能提供更经济的治疗选择。

局限性

  • 目前尚无关于结膜下曲安奈德注射治疗炎性黄斑水肿的已发表研究。
  • 尚无研究评估不同眼周和眼内策略治疗炎性黄斑水肿的有效性和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether they are injected peri- or intraocularly, corticosteroids are still essential tools in the therapeutic arsenal for treating inflammatory macular oedema. A few years ago, however, only triamcinolone acetonide was available to ophthalmologists. While this compound was initially developed for rheumatological or dermatological use, it has been increasingly deployed in ophthalmology, despite still being off-label. In 2011, the system for delivery of dexamethasone from a biodegradable, injectable implant into the vitreous cavity obtained approval for use in inflammatory macular oedema. While the efficacy and safety of triamcinolone in macular oedema, including inflammatory oedema, have already been studied, there are currently no publications on subconjunctival triamcinolone injections, which are simple, effective and well tolerated. To date, the dexamethasone 700 μg implant has been authorized for the treatment of noninfectious intermediate and posterior uveitis, but there have been no studies to evaluate the efficacy and safety of the different peri- and intraocular strategies, including the treatment of inflammatory macular oedema. METHODS: This protocol is therefore designed to compare the efficacy and safety of peri- and intraocular corticosteroid injections in the treatment of inflammatory macular oedema. In this ongoing study, 142 patients will be included, and the oedematous eye will be randomised to treatment with either subconjunctival triamcinolone injection or an intravitreal implant containing 700 μg dexamethasone. Follow-up is planned for 6 months with monthly visits. Each visit will include visual acuity measurement, a slit lamp examination, fundoscopy, intraocular pressure measurement, laser flare measurement (if available) and spectral domain optical coherence tomography. DISCUSSION: The results of this trial will have a real impact on public health if it is shown that a Kenacort retard® (i.e. triamcinolone) injection costing just €2.84 and performed in the physician's office (with no additional overhead costs) is at least as effective as the dexamethasone 700 μg implant (Ozurdex®; costing approximately €960 with the injection performed in a dedicated room), with no increased side effects. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02556424. Registered on 22 September 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Couret C, Poinas A, Volteau C, et al. Comparison of two techniques used in routine care for the treatment of inflammatory macular oedema, subconjunctival triamcinolone injection and intravitreal dexamethasone implant: medical and economic importance of this randomized controlled trial. Trials. 2020. PMID: 32041669. doi:10.1186/s13063-020-4066-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。